HF
IGMS

HRT Financial’s IGM Biosciences IGMS Stock Holding History

HRT Financial’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,762
Closed -$132K – 2907
2024
Q4 		$132K Buy
+21,762
New +$259K ﹤0.01% 2009
2023
Q3 		– Sell
-15,257
Closed -$140K – 2717
2023
Q2 		$140K Buy
+15,257
New +$171K ﹤0.01% 1922
2022
Q3 		– Sell
-70,661
Closed -$1.27M – 3124
2022
Q2 		$1.27M Buy
70,661
+13,075
+23% +$233K 0.01% 788
2022
Q1 		$1.54M Buy
57,586
+45,424
+373% +$846K 0.01% 763
2021
Q4 		$356K Buy
+12,162
New +$604K ﹤0.01% 2140
2021
Q3 		– Sell
-2,762
Closed -$229K – 3483
2021
Q2 		$229K Buy
+2,762
New +$205K ﹤0.01% 2311
2020
Q4 		– Sell
-16,805
Closed -$1.24M – 2125
2020
Q3 		$1.24M Buy
+16,805
New +$995K 0.04% 412

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

HRT Financial's IGMS Position: Q1 2025 in Review

HRT Financial sold out of IGM Biosciences (IGMS) in Q1 2025, closing a stake of 21,762 shares — an estimated $132K sold.

HRT Financial first reported a position in IGMS in Q3 2020 and held it in 7 quarters. The position peaked at $1.54M in Q1 2022. 79 funds tracked by Wall St. Rank hold IGMS as of Q1 2025.

  • HRT Financial reported no remaining IGM Biosciences position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 21,762 IGM Biosciences shares in Q1 2025, an estimated $132K.
  • HRT Financial first reported a position in IGM Biosciences in Q3 2020 and held it in 7 quarters.
  • HRT Financial's IGM Biosciences position peaked at $1.54M in Q1 2022.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.